A Phase 2 interventional study of Psilocybin (Usona Institute) in Depression, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Washington University School of Medicine · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing psilocybin in Depression — 26 open to participants now, 33 under way, 3 of them phase 3. Psilocybin · Depression.
Among the 48 studies testing psilocybin in Depression, this one is the 20th largest by planned enrollment, is one of 11 that started in 2026, is one of 29 in phase 2, reaches primary completion later than 31 of the 32 other live ones, and was the 43rd registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →26 of the 48 studies testing psilocybin in Depression are open now, in 7 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18–65
Rachel Yehuda · Sites in United States
Ages 18+
James J. Peters Veterans Affairs Medical Center · Sites in United States
Ages 22+
VA Office of Research and Development · Sites in United States
Ages 18–75
Yale University · Sites in United States
Ages 40–80
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 32 · Phase 3 4
First in 2004; this study’s year is marked. 11 started in 2026.
This study's planned enrollment of 50 is below the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 40 across the 48 interventional studies. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 48 have an industry lead sponsor. The 10 most frequent:
Washington University School of Medicine is the lead sponsor of 1,806 studies on the registry; 271 are open to participants now.
Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.
53 studies in Depression by Washington University School of Medicine: 6 open now, 8 under way, none of them phase 3. Of 44 finished, 23 (52%) have results posted.
Among the 53 studies in Depression by Washington University School of Medicine, this one is the 28th largest by planned enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 in phase 2, and was the 52nd registered.
Washington University School of Medicine’s Depression studies by the year they started, since 2001.
8 of the studies testing psilocybin in Depression that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07336238University of WashingtonGroup Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies | 2026-12-01 |
| NCT06355414Johns Hopkins UniversityPsilocybin in Chronic Low Back Pain and Depression | 2026-12-30 |
| NCT06200155M.D. Anderson Cancer CenterPsilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy | 2026-12-31 |
| NCT06782724University Medical Center GroningenPsilocybin Therapy for Psychological Distress in Palliative Patients | 2027-01-01 |
| NCT06801041M.D. Anderson Cancer CenterTRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors | 2027-03-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 48 studies testing psilocybin in Depression, from their registry updates:
Among Washington University School of Medicine’s 53 in Depression:
This tab as a report to print or save as PDF → With an account.
Depression is the leading cause of disability worldwide, affecting an estimated 300 million people. Despite available treatments, response rates remain modest, and treatment resistance is common. Novel treatments are needed that act rapidly, produce lasting effects and work differently than existing antidepressants.
In clinical trials, psilocybin has shown promise as a treatment for depression due to its rapid onset of antidepressant effects and sustained benefits.
This study will use MRI scanning of the brain and other biological measures (biomarkers) to investigate how psilocybin affects brain activity and psychological flexibility before, during, and after receiving psilocybin in participants with depressive symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has had Electroconvulsive Therapy, Transmagnetic Stimulation, Vagus Nerve Stimulation or Deep Brain Stimulation treatment within the last 12 months
a. Participants with VNS or DBS devices in place- including devices that are inactive or turned off will not be eligible to participate in the imaging portion of the study
Is currently taking a medication on the prohibited medications list, such as heterocyclic (tricyclic, tetracyclic) antidepressants, monoamine oxidase inhibitors (MAOIs), antipsychotic augmentation therapy, or is taking more than one medication for the treatment of depression:
Is at risk for hypertensive crisis defined as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Psilocybin (Usona Institute)
Capsule containing 25 mg of synthetic psilocybin
Characterize ACUTE (~1 week post-dose) and PERSISTING (~30 days post-dose) effects of PAT in depressed adults at two possible administrations on depression symptom severity using the Montgomery-Asberg Depression Rating Scale (MADRS) score.
The MADRS is a 10-item instrument used to assess depression severity. The total MADRS score ranges from 0-60, with higher scores indicating increased severity of depression
Time frame: 1 week and 30 days post-dose for both administration sessions
Characterize ACUTE (~1 week post-dose) and PERSISTING (~30 days post-dose) effects of PAT in depressed adults at two possible administrations on psychological flexibility using the Multidimensional Psychological Flexibility Inventory (MPFI).
The Multidimensional Psychological Flexibility Inventory (MPFI) is scored by averaging 60 items (or 24 in the short form) on a 1-6 scale (1 = "never true", 6 = "always true"). Higher average scores (1-6) indicate higher levels of the trait, with 12 subscales mapping onto psychological flexibility and inflexibility, allowing for detailed, sub-process, or global profiling.
Time frame: 1 week and 30 days post-dose for both administration sessions
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Nov 2026 (actual). Primary completion is estimated for Jun 2031, 55 months after the start.
Of 144 non-industry phase 2 interventional studies under Depression, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 55 months is above that.
Counting every sponsor, half of 198 studies reached it within 31 months; a quarter within 18 and three quarters within 47.
Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Nov 2026, on Nov 17, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Psilocybin
Washington University School of Medicine →